Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes

Bibliography

• GREEN BD, GAULT VA, O’HARTE FP, FLATT PR: Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. (2004) 10(29):3651-3662.
   PubMed Web of Science ®Google Scholar
• HOLST JJ: GLP-1 in NIDDM. Diabet. Med. (1996) 13(9):S156-S160.
   Google Scholar
• RUDOVICH NN, ROCHLITZ HJ, PFEIFFER AF: Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of Type 2 diabetic patients. Diabetes (2004) 53(9):2359-2365.
   PubMed Web of Science ®Google Scholar
• VALVERDE I, MORALES M, CLEMENTE F et al.: Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett. (1994) 349(2):313-316.
   PubMed Web of Science ®Google Scholar
• O’HARTE FP, GRAY AM, ABDEL-WAHAB YH, FLATT PR: Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides (1997) 18(9):1327-1333.
   PubMed Web of Science ®Google Scholar
• YANG H, EGAN JM, WANG Y et al.: GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am. J. Physiol. (1998) 275(3):C675-C683.
   PubMed Web of Science ®Google Scholar
• TRAPOTE MA, CLEMENTE F, GALERA C et al.: Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver. J. Endocrinol. Invest. (1996) 19(2):114-118.
   PubMed Web of Science ®Google Scholar
• MCINTOSH CH, BREMSAK I, LYNN FC et al.: Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin. Endocrinology (1999) 140(1):398-404.
   PubMed Web of Science ®Google Scholar
• MIYAWAKI K, YAMADA Y, BAN N et al.: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. (2002) 8(7):738-742.
   PubMed Web of Science ®Google Scholar
• OBEN J, MORGAN L, FLETCHER J, MARKS V: Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. (1991) 130(2):267-272.
   PubMed Web of Science ®Google Scholar
• EGAN JM, MONTROSE-RAFIZADEH C, WANG Y, BERNIER M, ROTH J: Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology (1994) 135(5):2070-2075.
   PubMed Web of Science ®Google Scholar
• BRUBAKER PL, DRUCKER DJ: Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology (2004) 145(6):2653-2659.
   PubMed Web of Science ®Google Scholar
• KIEFFER TJ, MCINTOSH CH, PEDERSON RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136(8):3585-3596.
   PubMed Web of Science ®Google Scholar
• ZANDER M, MADSBAD S, DEACON CF, HOLST JJ: The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with Type 2 diabetes. Diabetologia (2006) 49(2):369-374.
   PubMed Web of Science ®Google Scholar
• HINKE SA, GELLING RW, PEDERSON RA et al.: Dipeptidyl peptidase IV-resistant [d-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes (2002) 51(3):652-661.
   PubMed Web of Science ®Google Scholar
• KNUDSEN LB, PRIDAL L: Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. (1996) 318(2-3):429-435.
   PubMed Web of Science ®Google Scholar
• DEACON CF, PRIDAL L, KLARSKOV L, OLESEN M, HOLST JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. (1996) 271(3 Pt 1):E458-E464.
   PubMed Web of Science ®Google Scholar
• PRIDAL L, DEACON CF, KIRK O, CHRISTENSEN JV, CARR RD, HOLST JJ: Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. Eur. J. Drug Metab. Pharmacokinet. (1996) 21(1):51-59.
   PubMed Web of Science ®Google Scholar
• GREEN BD, GAULT VA, O’HARTE FP, FLATT PR: Development and therapeutic potential of incretin hormone analogues for Type 2 diabetes. The British Journal of Diabetes and Vascular Disease (2005) 5:134-140.
   Google Scholar
• DEACON CF, AHREN B, HOLST JJ: Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig. Drugs (2004) 13(9):1091-1102.
   PubMed Web of Science ®Google Scholar
• DRUCKER DJ: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of Type 2 diabetes. Expert Opin Investig. Drugs (2003) 12(1):87-100.
   PubMed Web of Science ®Google Scholar
• INZUCCHI SE: Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA (2002) 287(3):360-372.
   PubMed Web of Science ®Google Scholar
• KRENTZ AJ, BAILEY CJ: Oral antidiabetic agents: current role in Type 2 diabetes mellitus. Drugs (2005) 65(3):385-411.
   PubMed Web of Science ®Google Scholar
• ABBOTT CA, GORRELL MD: The family of CD26/DPIV and related ectopeptidases. In: Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidyl peptidase IV in Medicine and Biology. J Langer, S Ansorge (Eds), Kluwer/Plenum, New York, USA (2002):171-191.
   Google Scholar
• MENTLEIN R: Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul. Pept. (1999) 85(1):9-24.
   PubMed Web of Science ®Google Scholar
• GORRELL MD, GYSBERS V, MCCAUGHAN GW: CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand. J. Immunol. (2001) 54(3):249-264.
   PubMed Web of Science ®Google Scholar
• NIEDERMEYER J, ENENKEL B, PARK JE et al.: Mouse fibroblast-activation protein – conserved Fap gene organization and biochemical function as a serine protease. Eur. J. Biochem. (1998) 254(3):650-654.
   PubMedGoogle Scholar
• GORRELL MD: Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. (2005) 108(4):277-292.
   PubMed Web of Science ®Google Scholar
• AERTGEERTS K, LEVIN I, SHI L et al.: Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J. Biol. Chem. (2005) 280(20):19441-19444.
   PubMed Web of Science ®Google Scholar
• ABBOTT CA, YU D, MCCAUGHAN GW, GORRELL MD: Post-proline-cleaving peptidases having DP IV like enzyme activity. Post-proline peptidases. Adv. Exp. Med. Biol. (2000) 477:103-109.
   PubMed Web of Science ®Google Scholar
• MCDONALD JK, LEIBACH FH, GRINDELAND RE, ELLIS S: Purification of dipeptidyl aminopeptidase II (dipeptidyl arylamidase II) of the anterior pituitary gland: peptidase and dipeptide esterase activities. J. Biol. Chem. (1968) 243(15):4143-4150.
   PubMed Web of Science ®Google Scholar
• MAES MB, LAMBEIR AM, GILANY K et al.: Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem. J. (2005) 386(2):315-324.
   PubMed Web of Science ®Google Scholar
• LEITING B, PRYOR KD, WU JK et al.: Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. (2003) 371(2):525-532.
   PubMed Web of Science ®Google Scholar
• SENTEN K, VAN DER VEKEN P, BAL G et al.: Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(20):2825-2828.
   PubMed Web of Science ®Google Scholar
• AUGUSTYNS K, BAL G, THONUS G et al.: The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med. Chem. (1999) 6(4):311-327.
   PubMed Web of Science ®Google Scholar
• SCHON E, BORN I, DEMUTH HU et al.: Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol. Chem. Hoppe Seyler. (1991) 372(5):305-311.
   PubMed Web of Science ®Google Scholar
• STOCKEL-MASCHEK A, MRESTANI-KLAUS C, STIEBITZ B, DEMUTH H, NEUBERT K: Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim. Biophys. Acta (2000) 1479(1-2):15-31.
   PubMed Web of Science ®Google Scholar
• PROOST P, DE MEESTER I, SCHOLS D et al.: Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. (1998) 273(13):7222-7227.
   PubMed Web of Science ®Google Scholar
• STRUYF S, DE MEESTER I, SCHARPE S et al.: Natural truncation of RANTES abolishes signalling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. (1998) 28(4):1262-1271.
   PubMed Web of Science ®Google Scholar
• GEHLERT DR: Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides (1999) 33(5):329-338.
   PubMed Web of Science ®Google Scholar
• BATTERHAM RL, BLOOM SR: The gut hormone peptide YY regulates appetite. Ann. NY Acad. Sci. (2003) 994:162-168.
   PubMed Web of Science ®Google Scholar
• YADA T, SAKURADA M, IHIDA K et al.: Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet β-cells. J. Biol. Chem. (1994) 269(2):1290-1293.
   PubMed Web of Science ®Google Scholar
• YADA T, SAKURADA M, ISHIHARA H et al.: Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J. Physiol. (1997) 505:319-328.
   PubMed Web of Science ®Google Scholar
• GREEN BD, IRWIN N, FLATT PR: Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. Peptides (2006) 27(6):1349-1358.
   PubMed Web of Science ®Google Scholar
• LAMBEIR AM, DURINX C, PROOST P, VAN DAMME J, SCHARPE S, DE MEESTER I: Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. (2001) 507(3):327-330.
   PubMed Web of Science ®Google Scholar
• ZHU L, TAMVAKOPOULOS C, XIE D et al.: The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J. Biol. Chem. (2003) 278(25):22418-22423.
   PubMed Web of Science ®Google Scholar
• HINKE SA, POSPISILIK JA, DEMUTH HU et al.: Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J. Biol. Chem. (2000) 275(6):3827-3834.
   PubMed Web of Science ®Google Scholar
• HOLST JJ: Glucagon-like peptide-1: from extract to agent. Diabetologia (2006) 49(2):253-260.
   PubMed Web of Science ®Google Scholar
• NIKOLAIDIS LA, ELAHI D, SHEN YT, SHANNON RP: Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. (2005) 289(6):H2401-H2408.
   PubMed Web of Science ®Google Scholar
• MEIER JJ, GETHMANN A, NAUCK MA et al.: The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab. (2006) 290(6):E1118-E1123.
   PubMed Web of Science ®Google Scholar
• MARGUET D, BAGGIO L, KOBAYASHI T et al.: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA (2000) 97(12):6874-6879.
   PubMed Web of Science ®Google Scholar
• CONARELLO SL, LI Z, RONAN J et al.: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. USA (2003) 100(11):6825-6830.
   PubMed Web of Science ®Google Scholar
• NAGAKURA T, YASUDA N, YAMAZAKI K et al.: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. (2001) 284(2):501-506.
   PubMed Web of Science ®Google Scholar
• YASUDA N, NAGAKURA T, YAMAZAKI K, INOUE T, TANAKA I: Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci. (2002) 71:227-238.
   PubMed Web of Science ®Google Scholar
• HANSEN L, DEACON CF, ORSKOV C, HOLST JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology (1999) 140(11):5356-5363.
   PubMed Web of Science ®Google Scholar
• WEBER AE: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. (2004) 47(17):4135-4141.
   PubMed Web of Science ®Google Scholar
• MCINTOSH CH, DEMUTH HU, KIM SJ, POSPISILIK JA, PEDERSON RA: Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int. J. Biochem. Cell Biol. (2006) 38(5-6):860-872.
   PubMed Web of Science ®Google Scholar
• AUGERI DJ, ROBL JA, BETEBENUER DA et al.: Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. (2005) 48(15):5025-5037.
   PubMed Web of Science ®Google Scholar
• PEDERSON RA, WHITE HA, SCHLENZIG D, PAULY RP, MCINTOSH CH, DEMUTH HU: Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes (1998) 47(8):1253-1258.
   PubMed Web of Science ®Google Scholar
• HANSOTIA T, DRUCKER DJ: GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul. Pept. (2005) 128(2):125-134.
   PubMed Web of Science ®Google Scholar
• BALKAN B, KWASNIK L, MISERENDINO R, HOLST JJ, LI X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia (1999) 42(11):1324-1331.
   PubMed Web of Science ®Google Scholar
• DEACON CF, DANIELSEN P, KLARSKOV L, OLESEN M, HOLST JJ: Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycaemic effects in anesthetized pigs. Diabetes (2001) 50(7):1588-1597.
   PubMed Web of Science ®Google Scholar
• BURKEY BF, LI X, BOLOGNESE L et al.: Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J. Pharmacol. Exp. Ther. (2005) 315(2):688-695.
   PubMed Web of Science ®Google Scholar
• POSPISILIK JA, STAFFORD SG, DEMUTH HU et al.: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinaemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51(4):943-950.
   PubMed Web of Science ®Google Scholar
• POSPISILIK JA, MARTIN J, DOTY T et al.: Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes (2003) 52(3):741-750.
   PubMed Web of Science ®Google Scholar
• REIMER MK, HOLST JJ, AHREN B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. (2002) 146(5):717-727.
   PubMed Web of Science ®Google Scholar
• NAGAKURA T, YASUDA N, YAMAZAKI K, IKUTA H, TANAKA I: Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism (2003) 52(1):81-86.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI K, YASUDA N, INOUE T et al.: The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur. J. Pharmacol. (2004) 488(1-3):213-218.
   PubMed Web of Science ®Google Scholar
• JONES B, ADAMS S, MILLER GT, JESSON MI, WATANABE T, WALLNER BP: Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood (2003) 102(5):1641-1648.
   PubMed Web of Science ®Google Scholar
• LANKAS GR, LEITING B, ROY RS et al.: Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes (2005) 54(10):2988-2994.
   PubMed Web of Science ®Google Scholar
• HOFFMANN T, LUND K, MCINTOSH CH: DPP IV inhibition as treatment of Type 2 diabetes. In: Cell-surface aminopeptidases: basic and clinical aspects. S Mizupara (Ed.), Elsevier, New York, US (2001):381-387.
   Google Scholar
• AHREN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in Type 2 diabetes. Diabetes Care. (2002) 25(5):869-875.
   PubMed Web of Science ®Google Scholar
• AHREN B, LANDIN-OLSSON M, JANSSON PA, SVENSSON M, HOLMES D, SCHWEIZER A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes. J. Clin. Endocrinol. Metab. (2004) 89(5):2078-2084.
   PubMed Web of Science ®Google Scholar
• AHREN B, GOMIS R, STANDL E, MILLS D, SCHWEIZER A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care. (2004) 27(12):2874-2880.
   PubMed Web of Science ®Google Scholar
• AHREN B, PACINI G, FOLEY JE, SCHWEIZER A: Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1 year. Diabetes Care. (2005) 28(8):1936-1940.
   PubMed Web of Science ®Google Scholar
• DEJAGERS S, LEBEAUT A, COUTURIER A, SCHWIZER A: Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with Type 2 diabetes. Diabetes (2006) 55(Suppl. 1):A120.
   Google Scholar
• RISTIC S, BYIERS S, FOLEY J, HOLMES D: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with Type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes. Metab. (2005) 7(6):692-698.
   PubMed Web of Science ®Google Scholar
• D’ALESSIO DA, WATSON CE, HE Y-L et al.: Restoration of an acute insulin response to glucose in drug-naive patients with Type 2 diabetes by 3-month treatment with vildagliptin. Diabetes (2006) 55(Suppl. 1):A454.
   Google Scholar
• MARI A, SALLAS WM, HE YL et al.: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2005) 90(8):4888-4894.
   PubMed Web of Science ®Google Scholar
• STEVENS C, VAN DYCK K, YI B et al.: Single dose of MK-0431, an inhibitor of dipeptidyl peptidase-IV, raise active GLP-1 levels without causing hypoglycaemia in healthy subjects. Diabetes (2005) 54(Suppl. 1):493-P.
   Google Scholar
• HERMAN G, HANEFELD M, WU M, CHEN X, ZHAO P, STEIN P: Effect of MK-0431, a dipeptidyl peptidase IV (DPP IV) inhibitor, on glycaemic control after 12 weeks in patients with Type 2 diabetes. Diabetes (2005) 54(Suppl. 1):541-P.
   Google Scholar
• BRAZG R, THOMAS K, ZHAO P, XU L, CHEN X, STEIN P: Effect of adding MK-0431 to ongoing metformin therapy in Type 2 diabetic patients who have inadequate glycaemic control on metformin. Diabetes (2005) 54(Suppl. 1):11-OR.
   Google Scholar
• ASCHER P, KIPNES M, LUNCEFORD J, MICKEL C, DAVIES M, WILLIAMS-HERMAN D: Sitagliptin monotherapy improved glycaemic control in the fasting and postprandial states. Diabetes (2006) 55(Suppl. 1):A1995.
   Google Scholar
• KARASIK A, CHARBOUND B, LIU JI, WU M, MEEHAN A, MEININGER G: Sitagliptin added to ongoing metformin therapy enhanced glycaemic control and beta-cell function. Diabetes (2006) 55(Suppl. 1):A501.
   Google Scholar
• NIKOLAIDIS LA, ELAHI D, HENTOSZ T et al.: Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation (2004) 110(8):955-961.
   PubMed Web of Science ®Google Scholar
• BOSE AK, MOCANU MM, CARR RD, BRAND CL, YELLON DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 54(1):146-151.
   PubMed Web of Science ®Google Scholar
• VILSBOLL T, KRARUP T, SONNE J et al.: Incretin secretion in relation to meal size and body weight in healthy subjects and people with Type 1 and Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. (2003) 88(6):2706-2713.
   PubMed Web of Science ®Google Scholar
• DUPRE J, BEHME MT, HRAMIAK IM, MCDONALD TJ: Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care. (1997) 20(3):381-384.
   PubMed Web of Science ®Google Scholar
• MANNUCCI E, OGNIBENE A, CREMASCO F et al.: Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. (2001) 24(3):489-494.
   PubMed Web of Science ®Google Scholar
• LENHARD JM, CROOM DK, MINNICK DT: Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem. Biophys. Res. Commun. (2004) 324(1):92-97.
   PubMed Web of Science ®Google Scholar
• LINDSAY JR, DUFFY NA, MCKILLOP AM et al.: Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet. Med. (2005) 22(5):654-657.
   PubMed Web of Science ®Google Scholar
• HINKE SA, KUHN-WACHE K, HOFFMANN T, PEDERSON RA, MCINTOSH CH, DEMUTH HU: Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem. Biophys. Res. Commun. (2002) 291(5):1302-1308.
   PubMed Web of Science ®Google Scholar
• YASUDA N, INOUE T, NAGAKURA T et al.: Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem. Biophys. Res. Commun. (2002) 298(5):779-784.
   PubMed Web of Science ®Google Scholar
• HUPE-SODMANN K, MCGREGOR GP, BRIDENBAUGH R et al.: Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. (1995) 58(3):149-156.
   PubMed Web of Science ®Google Scholar
• HUPE-SODMANN K, GOKE R, GOKE B et al.: Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides (1997) 18(5):625-632.
   PubMed Web of Science ®Google Scholar
• PLAMBOECK A, HOLST JJ, CARR RD, DEACON CF: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia (2005) 48(9):1882-1890.
   PubMed Web of Science ®Google Scholar
• NAUCK MA, EL-OUAGHLIDI A: The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia (2005) 48(4):608-611.
   PubMed Web of Science ®Google Scholar
• MEST HJ, MENTLEIN R: Dipeptidyl peptidase inhibitors as new drugs for the treatment of Type 2 diabetes. Diabetologia (2005) 48(4):616-620.
   PubMed Web of Science ®Google Scholar
• DEACON CF, WAMBERG S, BIE P, HUGHES TE, HOLST JJ: Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. (2002) 172(2):355-362.
   PubMed Web of Science ®Google Scholar
• VILSBOLL T, HOLST JJ: Related Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia (2004) 47(3):357-366.
   PubMed Web of Science ®Google Scholar
• MENTLEIN R, GALLWITZ B, SCHMIDT WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. (1993) 214(3):829-835.
   PubMedGoogle Scholar
• BRUBAKER PL, IZZO A, HILL M, DRUCKER DJ: Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am. J. Physiol. (1997) 272(6 Pt 1):E1050-E1058.
   PubMed Web of Science ®Google Scholar
• BONGERS J, LAMBROS T, AHMAD M, HEIMER EP: Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta (1992) 1122(2):147-153.
   PubMed Web of Science ®Google Scholar
• NAUSCH I, MENTLEIN R, HEYMANN E: The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol. Chem. Hoppe Seyler. (1990) 371(11):1113-1118.
   PubMed Web of Science ®Google Scholar
• KATO T, NAGATSU T, FUKASAWA K, HARADA M, NAGATSU I, SAKAKIBARA S: Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase. Biochim. Biophys. Acta (1978) 525(2):417-422.
   PubMed Web of Science ®Google Scholar
• MENTLEIN R, DAHMS P, GRANDT D, KRUGER R: Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. (1993) 49(2):133-144.
   PubMed Web of Science ®Google Scholar
• SAKURADA C, SAKURADA S, HAYASHI T, KATSUYAMA S, TAN-NO K, SAKURADA T: Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem. Pharmacol. (2003) 66(4):653-661.
   PubMed Web of Science ®Google Scholar
• ZHANG XY, DE MEESTER I, LAMBEIR AM et al.: Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry. J. Mass Spectrom. (1999) 34(4):255-263.
   PubMed Web of Science ®Google Scholar
• HOFFMANN T, FAUST J, NEUBERT K, ANSORGE S: Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. (1993) 336(1):61-64.
   PubMed Web of Science ®Google Scholar
• SHANE R, WILK S, BODNAR RJ. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res. (1999) 815(2):278-286.
   PubMed Web of Science ®Google Scholar
• BOURAS M, HUNEAU JF, LUENGO C, ERLANSON-ALBERTSSON C, TOME D: Metabolism of enterostatin in rat intestine, brain membranes, and serum: differential involvement of proline-specific peptidases. Peptides (1995) 16(3):399-405.
   PubMed Web of Science ®Google Scholar
• ORAVECZ T, PALL M, RODERIQUEZ G et al.: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. (1997) 186(11):1865-1872.
   PubMed Web of Science ®Google Scholar
• SHIODA T, KATO H, OHNISHI Y et al.: Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. USA (1998) 95(11):6331-6336.
   PubMed Web of Science ®Google Scholar
• PROOST P, STRUYF S, SCHOLS D et al.: Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. (1999) 274(7):3988-3993.
   PubMed Web of Science ®Google Scholar